We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare ...

The drug was deemed too expensive for the UK's state-run health service in August. The EU regulator is expected to wrap up reexamining the drug's rejection this year, Biogen said. Leqembi is also ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug has been recommended by the European Medicines Agency’s human medicines ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Investors with a lot of money to spend have taken a bearish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

The UK approved Casgevy for sickle cell disease ... (see more details here) Biogen Inc.’s (NASDAQ:BIIB) approach can be traced back to the 2003 merger of Idec (the traditional blood cancer ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...